News

XCITE is an FDA fast tracked, pivotal Phase III trial of the company’s cancer drug Xilonix. XCITE is designed to assess improvement in overall survival of patients in

IGN002 is genetically engineered by fusing an antibody with interferon, a protein that plays a major role in regulating the immune system. The approved IND will allow Valor,

Compared to the existing standard of care chemotherapy ‘docetaxel’, the company noted that nivolumab is expected to offer significant superiority in survival rates. The approval of nivolumab, a

NICE has issued a final appraisal determination (FAD) for Lixiana to help patients with a heart flutter who have an increased risk of stroke. The draft guidance states

The money, which will be given over a five-year period, will help fund a program of six to eight research projects looking at new strategies to develop new

Following completion of the acquisition, the combined company will operate under the name Chiltern and will gain global reach mostly in China and Japan. It will also provide

The company noted that beta cells play a major role in the pathogenesis of diabetes, which currently affects 387 million patients across the world. Under the deal, beta

As of July 15, 2015, the latest overall survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the HEAT Study patients),

PH1 is a severe, rare, inherited disorder of the liver that often results in kidney failure and for which there are no approved therapies. Orphan Drug Designation by